Patents-Review.com
ClassID:

97270 ⎘

C07K2317/41 - page 3 - CPC Classification

Classification description:

Immunoglobulins specific features characterized by post-translational modification Glycosylation, sialylation, or fucosylation

Recent Application in this class:
#601
20200378982
2020-12-03

Method and system for analyzing N-linked sugar chains of glycoprotein

 #602
20200378950
2020-12-03

Glycosylation site-specific antibodies and anti-cancer compounds

 #603
20200369785
2020-11-26

IgG epitope and applications thereof as a drug target

 #604
20200369778
2020-11-26

Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases

 #605
20200362319
2020-11-19

O-Mannosyltransferase Deficient Filamentous Fungal Cells and Methods of Use Thereof

 #606
20200362028
2020-11-19

Nucleic acids encoding antibodies against IL-1 beta

 #607
20200362020
2020-11-19

Method for treating skin diseases using a humanized antibody that binds to vimentin

 #608
20200354465
2020-11-12

Methods Related to Alemtuzumab

 #609
20200354455
2020-11-12

Anti-CTLA-4 antibodies and methods of use thereof

 #610
20200340031
2020-10-29

Methods for measuring Renalase

 #611
20200339699
2020-10-29

Fully humanized anti-B cell maturation antigen (BCMA) single-chain antibody and use thereof

 #612
20200339696
2020-10-29

Methods of producing an IL-1 RAP antibodies

 #613
20200339684
2020-10-29

Anti-CD83 antibodies and use thereof

 #614
20200339673
2020-10-29

ILT7 binding molecules and methods of using the same

 #615
20200339666
2020-10-29

DNA-binding domain of CRISPR system, non-fucosylated and partially fucosylated proteins, and methods thereof

 #616
20200332022
2020-10-22

Inert format

 #617
20200332012
2020-10-22

Antigen Binding Molecules That Bind EGFR, Vectors Encoding Same, and Uses Thereof

 #618
20200325245
2020-10-15

GALACTOENGINEERED IMMUNOGLOBULIN 1 ANTIBODIES

 #619
20200325222
2020-10-15

Cancer stem cell-specific molecule

 #620
20200317804
2020-10-08

Optimized antibodies that target CD19

 #621
20200317796
2020-10-08

Methods of administering anti-OX40 antibodies

 #622
20200308293
2020-10-01

CD137 antibodies and tumor antigen-targeting antibodies and uses thereof

 #623
20200299382
2020-09-24

FcRn antibodies and methods of use thereof

 #624
20200291377
2020-09-17

Rapid and efficient de-glycosylation of glycoproteins

 #625
20200291133
2020-09-17

Antibodies to citrullinated proteins

 #626
20200291131
2020-09-17

Bispecific HER2 antibodies and methods of use

 #627
20200291120
2020-09-17

Antibodies that bind to c-type lectin domain family 2 member d (CLEC2D)

 #628
20200283543
2020-09-10

Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use

 #629
20200283524
2020-09-10

Bispecific polypeptide complexes

 #630
20200277642
2020-09-03

Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteins

 #631
20200277641
2020-09-03

GENETICALLY ENGINEERED EUKARYOTIC CELLS PRODUCING SIALYLATED GLYCOPROTEINS

 #632
20200277381
2020-09-03

ALPHA-V BETA-8 ANTIBODIES

 #633
20200277361
2020-09-03

Anti-transthyretin antibodies

 #634
20200277360
2020-09-03

C3B INACTIVATING POLYPEPTIDE

 #635
20200270366
2020-08-27

Bispecific antibodies against HER2 and CD3

 #636
20200270356
2020-08-27

Vectors comprising nucleic acids encoding anti-OX40 antibodies

 #637
20200268863
2020-08-27

Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers

 #638
20200262932
2020-08-20

Heterodimeric antibody Fc-containing proteins and methods for production thereof

 #639
20200255879
2020-08-13

Methods to produce single glycoform antibodies

 #640
20200255529
2020-08-13

Anti-TREM1 antibodies and related methods

 #641
20200255528
2020-08-13

B7-H4 antibodies and methods of use thereof

 #642
20200247860
2020-08-06

Light single-chain fusion polypeptides, encoding nucleic acid molecules and host cells

 #643
20200239554
2020-07-30

Antibodies that specifically bind to human complement factor C2b

 #644
20200231694
2020-07-23

PHARMACEUTICAL COMBINATIONS COMPRISING AN ANTI-BST-1 ANTIBODY AND A CYTIDINE ANALOGUE

 #645
20200231688
2020-07-23

ANTIBODY MOLECULES

 #646
20200223929
2020-07-16

Anti-epidermal growth factor receptor (EGFR) antibodies

 #647
20200223913
2020-07-16

ANTIBODY PURIFICATION AND PURITY MONITORING

 #648
20200223907
2020-07-16

Antibodies that target HIV GP120 and methods of use

 #649
20200222535
2020-07-16

BLyS antibody formulation

 #650
20200216871
2020-07-09

LABELING AND DETECTION OF POST TRANSLATIONALLY MODIFIED PROTEINS

 #651
20200216541
2020-07-09

ANTIBODY FORMULATION

 #652
20200216527
2020-07-09

Antibody variants

 #653
20200207842
2020-07-02

Anti-C5A antibodies

 #654
20200199248
2020-06-25

Bispecific HER2 and CD3 binding molecules

 #655
20200199229
2020-06-25

Humanized or chimeric CD3 antibodies

 #656
20200199224
2020-06-25

Anti-L1-CAM antibodies and uses thereof

 #657
20200197529
2020-06-25

Antigen binding proteins

 #658
20200197485
2020-06-25

Methods of use of soluble CD24 for treating immune related adverse events in cancer therapies

 #659
20200190186
2020-06-18

Antibodies against TIM3 and uses thereof

 #660
20200190167
2020-06-18

Polyomavirus neutralizing antibodies

 #661
20200181669
2020-06-11

Method for the production of a glycosylated immunoglobulin

 #662
20200181276
2020-06-11

Anti-GARP protein

 #663
20200181235
2020-06-11

METHODS OF USE OF SOLUBLE CD24 FOR NEUROPROTECTION AND REMYELINATION

 #664
20200181227
2020-06-11

Car T-cells recognizing cancer-specific IL 13Ra2

 #665
20200172947
2020-06-04

Process for manipulating the level of glycan content of a glycoprotein

 #666
20200172633
2020-06-04

COMMON LIGHT CHAINS AND METHODS OF USE

 #667
20200172622
2020-06-04

Bispecific binding proteins and uses thereof

 #668
20200172614
2020-06-04

Human PAC1 antibodies

 #669
20200172607
2020-06-04

FC-RECEPTOR BINDING MODIFIED ASYMMETRIC ANTIBODIES AND METHODS OF USE

 #670
20200171163
2020-06-04

Anti-CDH6 antibody and method of producing an anti-CDH6 antibody-drug conjugate

 #671
20200165649
2020-05-28

COMPOSITIONS AND METHODS RELATING TO UNIVERSAL GLYCOFORMS FOR ENHANCED ANTIBODY EFFICACY

 #672
20200165321
2020-05-28

Re-use of enzymes in in vitro glycoengineering of antibodies

 #673
20200165320
2020-05-28

IN VITRO GLYCOENGINEERING OF ANTIBODIES

 #674
20200164053
2020-05-28

Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers

 #675
20200157239
2020-05-21

REMOVAL OF TARGET CELLS BY CIRCULATING VIRUS-SPECIFIC CYTOTOXIC T-CELLS USING MHC CLASS I COMPRISING COMPLEXES

 #676
20200157200
2020-05-21

Anti-C5 antibodies having improved pharmacokinetics

 #677
20200148790
2020-05-14

Glycosylation of variable immunoglobulin domains

 #678
20200148785
2020-05-14

PD-L1 AND TA-MUC1 ANTIBODIES

 #679
20200148779
2020-05-14

MODIFIED IgG1 Fc DOMAINS AND ANTI-CD40 DOMAIN ANTIBODY FUSIONS THEREWITH

 #680
20200148777
2020-05-14

CANCER-ASSOCIATED IMMUNOSUPPRESSION INHIBITOR

 #681
20200148774
2020-05-14

Anti-CLL-1 antibodies and methods of use

 #682
20200140564
2020-05-07

Hyperglycosylated binding polypeptides

 #683
20200140546
2020-05-07

Anti-TREM2 antibodies and related methods

 #684
20200131518
2020-04-30

CONTROL OF TOTAL AFUCOSYLATED GLYCOFORMS OF ANTIBODIES PRODUCED IN CELL CULTURE

 #685
20200131275
2020-04-30

MULTISPECIFIC ANTIBODY CONSTRUCTS BINDING TO MUC1 AND CD3

 #686
20200131272
2020-04-30

ANTI-CD27 ANTIBODIES

 #687
20200123267
2020-04-23

Anti-transferrin receptor antibodies and methods of use

 #688
20200123253
2020-04-23

Antibody for treating autoimmune diseases

 #689
20200123252
2020-04-23

Bispecific antibodies against CEACAM5 and CD47

 #690
20200115470
2020-04-16

T cell receptor-like antibody agents specific for EBV latent membrane protein 2A peptide presented by human HLA

 #691
20200110094
2020-04-09

Fast protein sequencing

 #692
20200109195
2020-04-09

COMPOSITIONS AND METHODS FOR ENHANCING THE KILLING OF TARGET CELLS BY NK CELLS

 #693
20200109190
2020-04-09

Antibodies directed against leukotoxins

 #694
20200102400
2020-04-02

Engineered immunoglobulin Fc polypeptides displaying improved complement activation

 #695
20200095329
2020-03-26

Anti-CD30 antibodies and methods for treating CD30+ cancer

 #696
20200095323
2020-03-26

MITIGATING Fc-Fc RECEPTOR INTERACTIONS IN CANCER IMMUNOTHERAPY

 #697
20200095310
2020-03-26

Fc-receptor binding modified asymmetric antibodies and methods of use

 #698
20200087698
2020-03-19

Methods for increasing mannose content of recombinant proteins

 #699
20200087410
2020-03-19

HUMANIZED ANTI-CD40 ANTIBODIES

 #700
20200087404
2020-03-19

Method of screening for anti-GARP antibodies

 #701
20200087394
2020-03-19

ANTIBODIES TARGETING A LIGAND FROM AN IMMUNE CHECKPOINT, WITH AN FC FRAGMENT HAVING AN IMPROVED AFFINITY FOR CD16A

 #702
20200087391
2020-03-19

ANTIBODIES TO IL-6 AND USE THEREOF

 #703
20200087386
2020-03-19

Anti-transthyretin antibodies

 #704
20200080125
2020-03-12

METHOD FOR THE PRODUCTION OF A GLYCOSYLATED IMMUNOGLOBULIN

 #705
20200080124
2020-03-12

FUCOSYLATION-DEFICIENT CELLS

 #706
20200079873
2020-03-12

Anti-FAP antibodies and methods of use

 #707
20200079856
2020-03-12

Method of treating gastric cancer with anti-FGFR2-IIIb antibodies and modified FOLFOX6 chemotherapy

 #708
20200071738
2020-03-05

Increasing ornithine accumulation to increase high mannose glycoform content of recombinant proteins

 #709
20200071409
2020-03-05

Antibodies that bind to OX40 and their uses

 #710
20200062861
2020-02-27

Glycosynthase variants for glycoprotein engineering and methods of use

 #711
20200062859
2020-02-27

Anti-TIGIT antibodies

 #712
20200062857
2020-02-27

VARIANT TARGET BINDING AGENTS AND USES THEREOF

 #713
20200062851
2020-02-27

Activatable antibodies and methods of use thereof

 #714
20200062848
2020-02-27

HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH LIGAND 1 (PD-L1)

 #715
20200062837
2020-02-27

ANTI-NGF COMPOSITIONS AND USE THEREOF

 #716
20200061091
2020-02-27

Methods of inhibition of protein fucosylation in vivo using fucose analogs

 #717
20200055939
2020-02-20

Anti-MIC antibodies and methods of use

 #718
20200055923
2020-02-20

Antibody preparation

 #719
20200055921
2020-02-20

Methods for the treatment of neurodegeneration

 #720
20200054723
2020-02-20

ANTI-SIGLEC-8 ANTIBODIES AND METHODS OF USE THEREOF

 #721
20200048333
2020-02-13

ANTIGEN-BINDING DOMAINS OF THE MONOCLONAL ANTI-COLLAGEN I ANTIBODY

 #722
20200048304
2020-02-13

Production of heterodimeric proteins

 #723
20200040314
2020-02-06

O-mannosyltransferase deficient filamentous fungal cells and methods of use thereof

 #724
20200032312
2020-01-30

SIALYLATED GLYCOPROTEINS

 #725
20200031933
2020-01-30

COMPOSITION COMPRISING AVELUMAB

 #726
20200031923
2020-01-30

ANTAGONISTS OF IL-6 TO RAISE ALBUMIN AND/OR LOWER CRP

 #727
20200024357
2020-01-23

Antibodies that bind human CD39 and inhibit ATPase activity of a soluble extracellular domain human CD39 polypeptide

 #728
20200024344
2020-01-23

Compositions and methods for treating immune thrombocytopenia

 #729
20200024319
2020-01-23

Interleukin-2 muteins for the expansion of T-regulatory cells

 #730
20200022942
2020-01-23

Homogenous antibody drug conjugates via enzymatic methods

 #731
20200017575
2020-01-16

Human cytomegalovirus neutralizing antibodies and use thereof

 #732
20200010564
2020-01-09

ANTIBODIES THAT BIND NOVEL PCSK9 VARIANTS

 #733
20200010545
2020-01-09

Fc variants

 #734
20200009237
2020-01-09

Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers

 #735
20200003714
2020-01-02

High throughput interrogation of physiochemical properties of a protein

 #736
20200002435
2020-01-02

Thrombin-binding antibody molecules and uses thereof

 #737
20200002431
2020-01-02

BCMA antibodies and use of same to treat cancer and immunological disorders

 #738
20200002407
2020-01-02

Antibody neutralizing human respiratory syncytial virus

 #739
20190389965
2019-12-26

TREATMENT OF LUNG CANCER USING AN ANTI-FUCOSYL-GM1 ANTIBODY

 #740
20190389961
2019-12-26

Compositions and methods for treating cancer

 #741
20190381171
2019-12-19

CO-USE OF ANTI-BCMA ANTIBODY AND ANTIBODY-COUPLED T CELL RECEPTOR (ACTR) IN CANCER THERAPY AND B CELL DISORDERS

 #742
20190375835
2019-12-12

USE OF MONOCLONAL ANTIBODIES FOR THE TREATMENT OF INFLAMMATION AND BACTERIAL INFECTIONS

 #743
20190375819
2019-12-12

GLYCOSYLATED TRANSFERRIN RECEPTOR 1 TUMOR ANTIGEN

 #744
20190367570
2019-12-05

Chemoenzymatic glycoengineering of antibodies and FC fragments thereof

 #745
20190365889
2019-12-05

Catheter package including catheter straightening means

 #746
20190360016
2019-11-28

Methods for increasing mannose content of recombinant proteins

 #747
20190360015
2019-11-28

ANTIBODY COMPOSITION-PRODUCING CELL

 #748
20190359952
2019-11-28

Compositions and methods for reducing fucosylation of glycoproteins in insect cells and methods of use thereof for production of recombinant glycoproteins

 #749
20190359731
2019-11-28

USE OF HUMAN CELLS OF MYELOID LEUKAEMIA ORIGIN FOR EXPRESSION OF ANTIBODIES

 #750
20190359714
2019-11-28

Activatable anti-CTLA-4 antibodies and uses thereof

 #751
20190352410
2019-11-21

Nucleic acids encoding anti-OX40 antibodies

 #752
20190352396
2019-11-21

Aglycosylated antibody Fc region for treating cancer

 #753
20190352394
2019-11-21

ENZYMATIC MODIFICATION OF ANTI-AQP4 AUTOANTIBODY FOR MODULATING NEUROMYELITIS OPTICA

 #754
20190330377
2019-10-31

Polypeptide linker for preparing multispecific antibodies

 #755
20190330376
2019-10-31

PEPTIDES DERIVED FROM KININOGEN-1 FOR PROTEIN DRUGS IN VIVO HALF-LIFE EXTENSIONS

 #756
20190330369
2019-10-31

COMBINATION OF ANTI-CD303 AND ANTI-HER2 ANTIBODIES

 #757
20190328895
2019-10-31

Antibody-drug conjugates

 #758
20190328856
2019-10-31

Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers

 #759
20190322767
2019-10-24

HETERODIMERIC ANTIGEN BINDING PROTEINS

 #760
20190322763
2019-10-24

NOVEL IMMUNOCONJUGATES

 #761
20190322761
2019-10-24

Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof

 #762
20190322752
2019-10-24

Anti-CD25 antibody agents

 #763
20190322748
2019-10-24

Bispecific antibodies specific for PD1 and TIM3

 #764
20190322735
2019-10-24

Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist

 #765
20190316110
2019-10-17

Recombinant polypeptides comprising selenocysteine and method for producing the same

 #766
20190315883
2019-10-17

Immunoconjugates

 #767
20190309084
2019-10-10

Bispecific Polypeptides to GITR and CTLA-4

 #768
20190309081
2019-10-10

Anti-CD154 antibodies having impaired FcR binding and/or complement binding properties and related therapies

 #769
20190309064
2019-10-10

Anti-TREM2 antibodies and related methods

 #770
20190309058
2019-10-10

HIGHLY GALACTOSYLATED ANTI-TNF-ALPHA ANTIBODIES AND USES THEREOF

 #771
20190309057
2019-10-10

HIGHLY GALACTOSYLATED ANTI-TNF-ALPHA ANTIBODIES AND USES THEREOF

 #772
20190307878
2019-10-10

Immune complex

 #773
20190300618
2019-10-03

ANTI-CD27 ANTIBODIES

 #774
20190300613
2019-10-03

Anti-CD25 antibody agents

 #775
20190300612
2019-10-03

Anti-canine platelet derived growth factor receptor alpha antibody

 #776
20190300611
2019-10-03

Therapeutic CD47 antibodies

 #777
20190292269
2019-09-26

FC POLYPEPTIDE VARIANTS HAVING AN INCREASED HALF-LIFE

 #778
20190292268
2019-09-26

Methods for producing fabs and IgG bispecific antibodies

 #779
20190284568
2019-09-19

Production in plants of ricin antibodies that bind to ricin B chain

 #780
20190284560
2019-09-19

DNA aptamers binding to molecular targeted agents and detection method of molecular targeted medicine using the same

 #781
20190284298
2019-09-19

USE OF ANTIBODY-COUPLED T CELL RECEPTOR (ACTR) WITH MULTIPLE ANTI-CANCER ANTIBODIES IN CANCER TREATMENT

 #782
20190284291
2019-09-19

Anti-OX40 antibodies

 #783
20190284287
2019-09-19

Anti-CD25 antibody agents

 #784
20190276546
2019-09-12

Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists

 #785
20190270823
2019-09-05

Antibodies to CD70

 #786
20190270805
2019-09-05

ANTAGONISTS OF IL-6 TO PREVENT OR TREAT CACHEXIA, WEAKNESS, FATIGUE, AND/OR FEVER

 #787
20190263897
2019-08-29

Methods of treating atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria with anti-C5 antibodies

 #788
20190256600
2019-08-22

Antibodies directed against programmed death-1 (PD-1)

 #789
20190241671
2019-08-08

Anti-CD19 antibodies with reduced immunogenicity

 #790
20190233831
2019-08-01

Protease deficient filamentous fungal cells and methods of use thereof

 #791
20190233802
2019-08-01

Yeast strains producing mammalian-like complex n-glycans

 #792
20190233531
2019-08-01

Site-specific antibody-drug conjugation through glycoengineering

 #793
20190233518
2019-08-01

Anti-PD-1/LAG3 bispecific antibodies

 #794
20190233506
2019-08-01

Human Anti-Tau Antibodies

 #795
20190225706
2019-07-25

MODIFIED GLYCOPROTEIN, PROTEIN-CONJUGATE AND PROCESS FOR THE PREPARATION THEREOF

 #796
20190225694
2019-07-25

RECOMBINANT PRODUCTION OF MONOCLONAL ANTIBODIES

 #797
20190225691
2019-07-25

Anti-PD-L1 antibodies and variants

 #798
20190218282
2019-07-18

NOVEL ANTIBODY FORMAT

 #799
20190218275
2019-07-18

Immunoglobulin constant region Fc receptor binding agents

 #800
20190211115
2019-07-11

Methods for producing Fabs and bi-specific antibodies

 #801
20190211113
2019-07-11

BISPECIFIC ANTIBODIES WITH TETRAVALENCY FOR A COSTIMULATORY TNF RECEPTOR

 #802
20190211108
2019-07-11

Anti-podocalyxin antibody that targets tumor microenvironment

 #803
20190211083
2019-07-11

Human immunodeficiency virus neutralizing antibodies

 #804
20190211077
2019-07-11

Fc-binding protein, method for producing said protein, antibody adsorbent using said protein, and method for separating antibody using said adsorbent

 #805
20190209702
2019-07-11

Steroids and antibody-conjugates thereof

 #806
20190203247
2019-07-04

Production of N-glycoproteins for enzyme assisted glycomodification

 #807
20190202924
2019-07-04

Anti human interleukin-1 receptor accessory protein (IL1 RAP) antibodies and uses thereof

 #808
20190202911
2019-07-04

Methods for treating autoimmune diseases incorporating an anti-LAG3 antibody

 #809
20190202898
2019-07-04

AGLYCOSYLATED ANTI-C3b ANTIBODIES AND USES THEREOF

 #810
20190202889
2019-07-04

CD80 extracellular domain polypeptides and their use in cancer treatment

 #811
20190194711
2019-06-27

Endo-S2 mutants as glycosynthases, method of making and use for glycoengineering of glycoproteins

 #812
20190194338
2019-06-27

BCMA ANTIBODIES AND USE OF SAME TO TREAT CANCER AND IMMUNOLOGICAL DISORDERS

 #813
20190194303
2019-06-27

Methods for modifying human antibodies by glycan engineering

 #814
20190194288
2019-06-27

CD80 EXTRACELLULAR DOMAIN POLYPEPTIDES AND THEIR USE IN CANCER TREATMENT

 #815
20190185897
2019-06-20

METHODS FOR MODULATING PROTEIN GLYCOSYLATION PROFILES OF RECOMBINANT PROTEIN THERAPEUTICS USING MONOSACCHARIDES AND OLIGOSACCHARIDES

 #816
20190185583
2019-06-20

ANTI-CEA ANTIBODIES

 #817
20190185577
2019-06-20

Antibodies that recognize red blood cell antigens

 #818
20190185534
2019-06-20

CD40L single-chain fusion polypeptides and encoding nucleic acids

 #819
20190177438
2019-06-13

Site-specific crosslinking of antibodies

 #820
20190177432
2019-06-13

Host cell comprising nucleic acids encoding bispecific antibodies binding to beta-klotho and fibroblast growth factor receptor 1 and antibody production

 #821
20190177425
2019-06-13

Humanized and chimeric monoclonal antibodies to CD81

 #822
20190177423
2019-06-13

Anti-CD20 antibody

 #823
20190177419
2019-06-13

Anti-Axl antagonistic antibodies

 #824
20190177404
2019-06-13

Antibodies with engineered CH2 domains, compositions thereof and methods of using the same

 #825
20190175730
2019-06-13

Afucosylated anti-FGFR2IIIB antibodies

 #826
20190175592
2019-06-13

Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat b-cell proliferative disorders

 #827
20190169309
2019-06-06

REMOVAL OF CANCER CELLS BY CIRCULATING VIRUS-SPECIFIC CYTOTOXIC T-CELLS USING CANCER CELL TARGETED MHC CLASS 1 COMPROMISING MULTI-FUNCTION PROTEINS

 #828
20190169288
2019-06-06

Antagonists of IL-6 to prevent or treat thrombosis

 #829
20190169283
2019-06-06

Anti-CXCR5 antibodies and compositions and uses thereof

 #830
20190169278
2019-06-06

Anti-polyubiquitin multispecific antibodies

 #831
20190169274
2019-06-06

HUMAN ANTI-TAU ANTIBODIES

 #832
20190169271
2019-06-06

Use of a long acting GLP-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease

 #833
20190161546
2019-05-30

SP35 Antibodies And Uses Thereof

 #834
20190161540
2019-05-30

ANTI-NERVE GROWTH FACTOR ANTIBODIES AND METHODS OF PREPARING AND USING THE SAME

 #835
20190153497
2019-05-23

Methods for modulating protein galactosylation profiles of recombinant proteins using peracetyl galactose

 #836
20190153496
2019-05-23

Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins

 #837
20190153116
2019-05-23

Antibody binding to carbonic anhydrase and use thereof

 #838
20190153110
2019-05-23

PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF

 #839
20190153073
2019-05-23

ANTIBODIES THAT NEUTRALIZE RSV, MPV AND PVM AND USES THEREOF

 #840
20190151448
2019-05-23

Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration

 #841
20190151446
2019-05-23

Monomeric proteins and uses thereof

 #842
20190144544
2019-05-16

PD-L1 Antibodies

 #843
20190135919
2019-05-09

Anti-CTLA-4 antibodies and methods of use thereof

 #844
20190135901
2019-05-09

Glycosylated repeat-motif-molecule conjugates

 #845
20190127455
2019-05-02

Treatment of Ocular Diseases with Fully- Human Post-Translationally Modified Anti-VEGF Fab

 #846
20190127451
2019-05-02

Non-glycosylated anti-tenascin antibody

 #847
20190127446
2019-05-02

Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods

 #848
20190119713
2019-04-25

COMPOSITIONS AND METHODS RELATING TO UNIVERSAL GLYCOFORMS FOR ENHANCED ANTIBODY EFFICACY

 #849
20190119395
2019-04-25

Combination therapy using an anti-fucosyl-GM1 antibody and an anti-CD137 antibody

 #850
20190112393
2019-04-18

ANTIGEN-BINDING MOLECULE FOR PROMOTING ELIMINATION OF ANTIGENS

 #851
20190112382
2019-04-18

Humanized antibodies against CD269 (BCMA)

 #852
20190112358
2019-04-18

DNA-binding domain of CRISPR system, non-fucosylated and partially fucosylated proteins, and methods thereof

 #853
20190112349
2019-04-18

MODIFIED CHIMERIC RECEPTORS AND USES THEREOF IN IMMUNE THERAPY

 #854
20190106499
2019-04-11

Antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases

 #855
20190106498
2019-04-11

TREATMENT FOR ACUTE MYELOID LEUKEMIA

 #856
20190106496
2019-04-11

Methods Of Identifying Anti-Inflammatory Compounds

 #857
20190105348
2019-04-11

CHIMERIC RECEPTORS AND USES THEREOF IN IMMUNE THERAPY

 #858
20190100573
2019-04-04

Methods for modifying human antibodies by glycan engineering

 #859
20190092852
2019-03-28

Anti-interleukin-33 antibodies and uses thereof

 #860
20190091332
2019-03-28

Anti-LAG3 antibodies and antigen-binding fragments

 #861
20190091312
2019-03-28

Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers

 #862
20190085370
2019-03-21

PROCESS FOR MANIPULATING THE LEVEL OF GLYCAN CONTENT OF A GLYCOPROTEIN

 #863
20190085080
2019-03-21

B7-H4 antibodies and methods of use thereof

 #864
20190085071
2019-03-21

Antagonists to IL-6 to Raise Albumin and/or Lower CRP

 #865
20190083615
2019-03-21

Anti-LAG3 antibodies and antigen-binding fragments

 #866
20190083614
2019-03-21

Anti-LAG3 antibodies and antigen-binding fragments

 #867
20190083587
2019-03-21

Coagulation factor-targeting to TREM-like transcript 1 (TLT-1) on activated platelets

 #868
20190079101
2019-03-14

METHODS OF EVALUATING AND MAKING BIOLOGICS

 #869
20190077864
2019-03-14

TIGIT-binding agents and uses thereof

 #870
20190071518
2019-03-07

PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ADAM17 SUBSTRATE DEPENDENT CANCERS

 #871
20190071514
2019-03-07

ANTI-CD39 ANTIBODIES

 #872
20190071512
2019-03-07

Fc variants with increased affinity for FcγRIIc

 #873
20190071511
2019-03-07

IMMUNOGLOBULIN VARIANTS AND USES THEREOF

 #874
20190071491
2019-03-07

Anti-transthyretin antibodies

 #875
20190071488
2019-03-07

Polyomavirus neutralizing antibodies

 #876
20190064171
2019-02-28

Early detection of hepatocellular carcinoma

 #877
20190060481
2019-02-28

Glycoengineered antibody drug conjugates

 #878
20190060399
2019-02-28

GLYCOPEPTIDES AND USES THEREOF

 #879
20190048078
2019-02-14

Engineered antibody Fc variants for enhanced serum half life

 #880
20190031784
2019-01-31

T CELL ACTIVATING BISPECIFIC ANTIGEN BINDING MOLECULES

 #881
20190031738
2019-01-31

Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods

 #882
20190031737
2019-01-31

Polypeptides With Enhanced Anti-Inflammatory And Decreased Cytotoxic Properties And Relating Methods

 #883
20190030160
2019-01-31

Methods for improving safety of blood-brain barrier transport

 #884
20190025325
2019-01-24

Methods related to biologics

 #885
20190024129
2019-01-24

FUCOSYLATION-DEFICIENT CELLS

 #886
20190024066
2019-01-24

Cells producing Fc containing molecules having altered glycosylation patterns and methods and use thereof

 #887
20190023801
2019-01-24

BCMA ANTIBODIES AND USE OF SAME TO TREAT CANCER AND IMMUNOLOGICAL DISORDERS

 #888
20190023769
2019-01-24

Compositions and methods for inhibiting pathogen infection

 #889
20190023759
2019-01-24

CD27 ligand (CD27L) single-chain fusion polypeptides

 #890
20190016813
2019-01-17

Anti-CD43 antibody and use thereof for cancer treatment

 #891
20190016811
2019-01-17

Antibody against a complex between human GARP and latent TGF-β

 #892
20190016786
2019-01-17

Broadly neutralizing HIV-1 antibodies that bind to the CD4-binding site of the envelope protein

 #893
20190016753
2019-01-17

METHODS FOR SEPARATING ISOFORMS OF MONOCLONAL ANTIBODIES

 #894
20190010532
2019-01-10

Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins

 #895
20190010225
2019-01-10

Antagonists of IL-6 to raise albumin and/or lower CRP

 #896
20190002946
2019-01-03

Methods for increasing mannose content of recombinant proteins

 #897
20190002945
2019-01-03

Generation and comparative kinetic analysis of new glycosynthase mutants from endoglycosidases for antibody glycoengineering

 #898
20190002542
2019-01-03

Transglycosylation of endo-S and endo-S mutants for antibody glycosylation remodeling

 #899
20190002533
2019-01-03

Polyomavirus neutralizing antibodies

 #900
20180371079
2018-12-27

Antibodies to IL-6 and use thereof